38; 95% CI = 1.12-1.66; P = 0.004 for heterogeneity) or Ile/Val and Val/Val combined vs Ile/Ile (OR = 1.42;

95% CI = 1.18-1.70; P = 0.007 for heterogeneity. However, among lung AC and SCLC, no significant associations were observed for both Val/Val vs Ile/Ile or Ile/Val and Val/Val combined vs Ile/Ile (Figure 7). Figure 7 Forest www.selleckchem.com/products/acalabrutinib.html plot (random-effects model) of lung cancer risk associated with CYP1A1 exon7 genotype for the combined Ile/Val and Val/Val vs Ile/Ile by histological types of lung cancer. Eight [36, 54, 56, 57, 70, 74, 76, 77] out of 64 studies included the association of CYP1A1 exon 7 genotype and lung caner risk stratified by gender (Male and Female). For Dabrafenib supplier Female population (3 studies), significantly increased risks were observed for both Val/Val vs Ile/Ile (OR = 1.29; 95% CI = 1.08-1.51; P = 0.000 for heterogeneity), Ile/Val and Val/Val combined vs Ile/Ile (OR = 1.24; 95% CI = 1.05-1.47; P = 0.002 for heterogeneity). However, for Male population (7 studies), no significant selleck chemicals llc associations were observed for both Val/Val vs Ile/Ile (OR = 1.18; 95% CI = 0.92-1.35; P = 0.360 for heterogeneity) or Ile/Val and Val/Val combined vs Ile/Ile (OR = 1.15; 95% CI = 0.96-1.39; P = 0.298 for heterogeneity) (Figure 8). Figure 8 Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 exon7 genotype for the combined Ile/Val and Val/Val vs Ile/Ile stratified by gender of population.

Ten [24, 31, 56, 60, 70–73] out of 64 studies included the association of CYP1A1 exon 7 genotype and lung caner risk stratified

by smoking status (non-smokers or never smokers and smokers). For smokers, significantly increased risks were observed for both Val/Val vs Ile/Ile (OR = 1.84; 95% CI = 1.36-2.08; P = 0.003 for heterogeneity), Ile/Val and Val/Val combined vs Ile/Ile (OR = 1.62; 95% CI = 1.24-2.11; P = 0.004 for heterogeneity). However, for non-smokers, no significant associations were observed for both Val/Val vs Ile/Ile (OR = 1.18; 95% CI = 0.96-1.38; P = 0.080 for heterogeneity) or Ile/Val and Val/Val combined vs Ile/Ile (OR = 1.07; 95% CI = 0.88-1.31; P = 0.002 for heterogeneity) (Figure 9). Figure 9 Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 exon7 genotype for the combined Ile/Val and Val/Val vs Ile/Ile ADAMTS5 stratified by smoking status of population. 3.3 Sensitivity analyses On omission of each individual study, the corresponding pooled OR was not altered materially (data not shown). 3.4 Publication bias Begg’s funnel plot and Egger’s test were performed to identify any publication bias. The funnel plots did not exhibit any patent asymmetry (Figure 10 and 11). By Egger’s test–used to provide statistical evidence of funnel plot symmetry–there was no evidence of publication bias (P = 0.558 for publication bias of MspI and P = 0.722 for publication bias of exon 7).